Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | TTR | P02766 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | UNG | P13051 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CDH1 | P12830 | 1/20 | 0.44 |
| ▸ | APC | P25054 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11540033 | 0.84 | TSHR (0.61) | TSHRTDP1SRD5A2ERN1TTR | |
| SCHEMBL28259354 | 0.82 | TDP1 (0.48) | TSHRTDP1SRD5A2ERN1TTR | |
| SCHEMBL4918747 | 0.81 | ALDH1A1 (0.52) | TSHRTDP1ERN1ALDH1A1MAPT | |
| SCHEMBL29941258 | 0.81 | ALDH1A1 (0.52) | TSHRTDP1ERN1ALDH1A1MAPT | |
| SCHEMBL25212775 | 0.79 | TDP1 (0.50) | TDP1KDM4E | |
| SCHEMBL7402751 | 0.79 | TSHR (0.55) | TSHRSRD5A2TTRALDH1A1MAPT | |
| SCHEMBL7402750 | 0.79 | TSHR (0.55) | TSHRSRD5A2TTRALDH1A1MAPT | |
| SCHEMBL3647722 | 0.78 | ALDH1A1 (0.53) | TDP1ERN1ALDH1A1MAPTALOX15 | |
| SCHEMBL8650814 | 0.78 | TTR (0.60) | TSHRSRD5A2TTRALDH1A1ALOX15 | |
| SCHEMBL8650815 | 0.78 | TTR (0.60) | TSHRSRD5A2TTRALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| EP-4114829-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2023-01-11 | — | — | EP | disclosed |
| CN-113493444-A | Compound and preparation method and application thereof | 深圳华大生命科学研究院 | 2021-10-12 | — | — | CN | disclosed |
| EP-3875452-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-09-08 | — | — | EP | disclosed |
| EP-3875452-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-09-08 | — | — | EP | disclosed |
| WO-2021160132-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2021-08-19 | — | — | WO | disclosed |
| EP-3292101-B1 | TRICYCLIC SULFONES AS ROR-GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-107709295-B | Tricyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2021-05-04 | — | — | CN | disclosed |
| WO-2020243135-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| EP-1466912-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-0912567-B1 | CARBOLINE DERIVATIVES | ICOS CORP (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6306870-B1 | PHOSPHODIESTERASE ENZYME INHIBITORS, CARDIOVASCULAR DISORDERS AND SEXUAL DISORDERS | ICOS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-6117881-A | POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE | ICOS CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| US-6043252-A | A POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP-SPECIFIC PDE); TREATING CARDIOVASCULAR DISORDERS AND ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0912567-A1 | CARBOLINE DERIVATIVES | ICOS CORPORATION (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997043287-A1 | CARBOLINE DERIVATIVES | ICOS CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0240256-B1 | COMPOUNDS USEFUL IN TREATING SICKLE CELL ANEMIA | MERCK & CO. INC. (US) | 1992-04-29 | — | — | EP | disclosed |
| US-4751244-A | NITROALKENYL CARBOXYLIC ACIDS | MERCK & CO., INC. (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0240256-A2 | Compounds useful in treating sickle cell anemia | MERCK & CO. INC. (US) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPA | TSHR 4078/4885TDP1 2433/4885SRD5A2 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.